On January 16, 2020, Genprex, Inc. (the "Company") reported that it has entered into a securities purchase agreement (the "Securities Purchase Agreement") with an accredited investor identified on the signature page thereto (the "Purchaser") pursuant to which the Company agreed to issue and sell to the Purchaser an aggregate of 961,000 shares (the "Shares") of its common stock, par value $0.001 per share (the "Common Stock"), in a registered direct offering (the "Registered Direct Offering") (Filing, 8-K, Genprex, JAN 16, 2020, View Source [SID1234553309]). The Shares were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-233774) filed with the Securities and Exchange Commission (the "Commission") on September 16, 2019, as amended on October 4, 2019 (as amended, the "Registration Statement") and declared effective on October 28, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The purchase price for one Share in the Registered Direct Offering was $0.24. The closing of the Registered Direct Offering is anticipated to occur on January 21, 2020. The Company expects the aggregate net proceeds from the Offerings, after deducting estimated offering expenses, to be approximately $200,000. The Company intends to use the aggregate net proceeds for working capital and other general corporate purposes.

The Securities Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing.

The foregoing description of the material terms of the Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Securities Purchase Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

The representations, warranties and covenants contained in the Securities Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Securities Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Securities Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Securities Purchase Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the Commission.

The legal opinion, including the related consent, of Sheppard Mullin Richter & Hampton, LLP relating to the issuance and sale of the Shares is filed as Exhibit 5.1 hereto.

This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On January 16, 2020 AgilVax, Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and KRAS inhibitors, reported that it closed an expansion of its Series A-1 financing with an additional investment of $1.5 million from its existing investors, bringing the total capital raised to nearly $10 million (Press release, Agilvax, JAN 16, 2020, View Source [SID1234553290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This additional investment reflects the confidence of our existing investors and allows AgilVax to continue generating compelling preclinical data with our monoclonal antibody-drug conjugates targeting SLC7A11 (xCT)," stated Dr. Joseph Patti, President and Chief Executive Officer of AgilVax. Dr. Patti further stated, "xCT overexpression is often associated with KRAS mutations in several cancers and its biological role is involved with critical cellular metabolic changes that lead to tumor progression. AgilVax’s antibody-based therapeutics have shown the ability to reduce primary tumor formation and the number of lung metastases in an animal model illustrating the potential to create durable responses in patients suffering from various metastatic cancers."

Ebetuel Pallares, PhD, AgilVax’s Chairman, said, "The team is making excellent progress developing their antibody-based programs for multiple oncology indications and we are excited to support this important research."

On January 16, 2020 I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, reported the pricing of its initial public offering of 7,407,400 American Depositary Shares ("ADSs"), each ten (10) ADSs representing twenty-three (23) ordinary shares of the Company, par value US$0.0001 per share, at US$14.00 per ADS, assuming the underwriters do not exercise their option to purchase additional ADSs (Press release, I-Mab Biopharma, JAN 16, 2020, View Source [SID1234553310]). The ADSs will begin trading on January 17, 2020 on the Nasdaq Global Market under the symbol "IMAB."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has granted the underwriters an option to purchase up to an additional 1,111,110 ADSs within 30 days from the date of the final prospectus at US$14.00 per ADS. The total gross proceeds of the offering are expected to be approximately US$ 103,703,600, assuming the underwriters do not exercise their option to purchase additional ADSs, or approximately US$ 119,259,140, if the underwriters choose to exercise their option to purchase additional ADSs in full.

Jefferies LLC and China International Capital Corporation Hong Kong Securities Limited are acting as joint book-running managers for this offering. China Renaissance Securities (Hong Kong) Limited and Huatai Securities (USA), Inc. are acting as lead managers for this offering.

The Company’s registration statement related to the offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus related to the offering may be obtained from (i) Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by e-mail at [email protected] or (ii) China International Capital Corporation Hong Kong Securities Limited, Attn: Rita Li, 29th One International Finance Center, One Harbour View Street, Central, Hong Kong, by telephone at (852) 2872-2000 or by e-mail at [email protected].

On January 16, 2020 Admera Health reported that will present in the PMWC 2020 Clinical Diagnostics Showcase for selected organizations, to exhibit their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients (Press release, Admera Health, JAN 16, 2020, View Source [SID1234553273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event | Location: Precision Medicine World Conference 2020 | Santa Clara Convention Center
Presenter: Ruben Bonilla-Guerrero, MD, FACMG, FAACC, Medical Director, Admera Health
Date | Time: Friday, January 24th, 2020 | 11:30 a.m. Pacific Time
Program | Track: Silicon Valley Program | Track 6

On January 16, 2020 Mundipharma reported a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong (Press release, Mundipharma, JAN 16, 2020, View Source [SID1234553291]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).

Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.

"This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments," said Mundipharma CEO, Raman Singh. "This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments," he added.